These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37953355)

  • 81. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 82. On the different response of Salmonella typhimurium hisG46 and TA1530 to mutagenic action of base analogues.
    Janion C
    Acta Biochim Pol; 1979; 26(1-2):171-7. PubMed ID: 388954
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N
    Bluemling GR; Mao S; Natchus MG; Painter W; Mulangu S; Lockwood M; De La Rosa A; Brasel T; Comer JE; Freiberg AN; Kolykhalov AA; Painter GR
    Antiviral Res; 2023 Jan; 209():105453. PubMed ID: 36379378
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Identification of critical host mitochondrion-associated genes during Ehrlichia chaffeensis infections.
    Von Ohlen T; Luce-Fedrow A; Ortega MT; Ganta RR; Chapes SK
    Infect Immun; 2012 Oct; 80(10):3576-86. PubMed ID: 22851751
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Santos-Ferreira N; Van Dycke J; Chiu W; Neyts J; Matthijnssens J; Rocha-Pereira J
    Antiviral Res; 2024 Mar; 223():105839. PubMed ID: 38373532
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Template properties of mutagenic cytosine analogues in reverse transcription.
    Suzuki T; Moriyama K; Otsuka C; Loakes D; Negishi K
    Nucleic Acids Res; 2006; 34(22):6438-49. PubMed ID: 17130163
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Molecular mechanism of N4-aminocytidine mutagenesis].
    Negishi K
    Yakugaku Zasshi; 1990 May; 110(5):293-303. PubMed ID: 2198343
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Phosphorylation of uridine and cytidine by uridine-cytidine kinase.
    Qian Y; Ding Q; Li Y; Zou Z; Yan B; Ou L
    J Biotechnol; 2014 Oct; 188():81-7. PubMed ID: 25160914
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative.
    Appleby TC; Larson G; Cheney IW; Walker H; Wu JZ; Zhong W; Hong Z; Yao N
    Acta Crystallogr D Biol Crystallogr; 2005 Mar; 61(Pt 3):278-84. PubMed ID: 15735337
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Mutagenicity of N4-aminocytidine and its derivatives in Chinese hamster lung V79 cells. Incorporation of N4-aminocytosine into cellular DNA.
    Nomura A; Negishi K; Hayatsu H; Kuroda Y
    Mutat Res; 1987 Apr; 177(2):283-7. PubMed ID: 3561428
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antiviral activity of nucleoside analogues against norovirus.
    Costantini VP; Whitaker T; Barclay L; Lee D; McBrayer TR; Schinazi RF; Vinjé J
    Antivir Ther; 2012; 17(6):981-91. PubMed ID: 22910194
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
    Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
    Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
    [TBL] [Abstract][Full Text] [Related]  

  • 94. New insights into the pyrimidine salvage pathway of Saccharomyces cerevisiae: requirement of six genes for cytidine metabolism.
    Kurtz JE; Exinger F; Erbs P; Jund R
    Curr Genet; 1999 Sep; 36(3):130-6. PubMed ID: 10501935
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Molnupiravir: First Approval.
    Syed YY
    Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
    Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
    Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells.
    Koizumi K; Shimamoto Y; Azuma A; Wataya Y; Matsuda A; Sasaki T; Fukushima M
    Int J Mol Med; 2001 Sep; 8(3):273-8. PubMed ID: 11494055
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Crystallization and preliminary X-ray analysis of human uridine-cytidine kinase 2.
    Suzuki NN; Koizumi K; Fukushima M; Matsuda A; Inagaki F
    Acta Crystallogr D Biol Crystallogr; 2003 Aug; 59(Pt 8):1477-8. PubMed ID: 12876357
    [TBL] [Abstract][Full Text] [Related]  

  • 99. An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.
    Marikawa Y; Alarcon VB
    Reprod Toxicol; 2023 Oct; 121():108475. PubMed ID: 37748715
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts.
    Blaney SM; Grem JL; Balis FM; Cole DE; Adamson PC; Poplack DG
    Biochem Pharmacol; 1993 Apr; 45(7):1493-501. PubMed ID: 8471071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.